MedPath

Mines D`or Orbec Inc

Mines D`or Orbec Inc logo
🇺🇸United States
Ownership
Public
Established
1993-01-01
Employees
375
Market Cap
$121.4M
Website
http://www.bluebirdbio.com
Introduction

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Clinical Trials

45

Active:30
Completed:9

Trial Phases

3 Phases

Phase 1:30
Phase 2:1
Phase 3:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (38 trials with phase data)• Click on a phase to view related trials

Phase 1
30 (78.9%)
Phase 3
7 (18.4%)
Phase 2
1 (2.6%)

A Study of Participants With β-Thalassemia Treated With Betibeglogene Autotemcel

Recruiting
Conditions
Beta-Thalassemia
First Posted Date
2024-02-21
Last Posted Date
2025-02-11
Lead Sponsor
bluebird bio
Target Recruit Count
150
Registration Number
NCT06271512
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

🇺🇸

UCSF Benioff Children's Hospitals, Oakland, California, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

and more 3 locations

A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

Recruiting
Conditions
Cerebral Adrenoleukodystrophy (CALD)
First Posted Date
2024-01-25
Last Posted Date
2025-07-02
Lead Sponsor
bluebird bio
Target Recruit Count
120
Registration Number
NCT06224413
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy

Conditions
Sickle Cell Disease
First Posted Date
2020-11-13
Last Posted Date
2025-03-20
Lead Sponsor
bluebird bio
Target Recruit Count
85
Registration Number
NCT04628585
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

🇺🇸

University of Alabama, Birmingham, Alabama, United States

🇺🇸

UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

and more 13 locations

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

Phase 3
Active, not recruiting
Conditions
Sickle Cell Disease
First Posted Date
2020-03-03
Last Posted Date
2024-12-10
Lead Sponsor
bluebird bio
Target Recruit Count
35
Registration Number
NCT04293185
Locations
🇺🇸

University of Alabama, Birmingham, Alabama, United States

🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

🇺🇸

Tufts Medical Center, Boston, Massachusetts, United States

and more 6 locations

A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Phase 3
Completed
Conditions
Cerebral Adrenoleukodystrophy (CALD)
First Posted Date
2019-02-25
Last Posted Date
2024-05-24
Lead Sponsor
bluebird bio
Target Recruit Count
35
Registration Number
NCT03852498
Locations
🇺🇸

Lucile Packard Children's Hospital, Palo Alto, California, United States

🇺🇸

Boston Children's Hospital/Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

and more 5 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

FDA Restricts Bluebird Bio's Skysona Gene Therapy Following Tripled Cancer Risk

The FDA has restricted Skysona gene therapy to cerebral adrenoleukodystrophy patients without alternative treatments after hematologic malignancy rates tripled to 15%.

CMS Launches Multi-State Payment Model to Expand Access to Sickle Cell Gene Therapies

The Centers for Medicare & Medicaid Services unveiled a new outcomes-based payment model with 33 states to expand Medicaid access to gene therapies for sickle cell disease.

bluebird bio Strengthens Leadership Team with Three Key Executive Appointments

bluebird bio, a pioneer in gene therapies for severe genetic diseases, has appointed three new executives to strengthen its leadership team as the company focuses on commercial execution.

National Resilience Winds Down Six Manufacturing Facilities Despite $2.25 Billion in Total Funding

National Resilience announced plans to wind down six manufacturing facilities across California, Massachusetts, and Florida, citing that capacity expansion has outpaced industry demand.

Carlyle and SK Capital Complete $3-5 Per Share Acquisition of Gene Therapy Pioneer bluebird bio

Carlyle and SK Capital Partners successfully acquired 59.8% of bluebird bio shares through a tender offer that expired May 29, 2025, meeting all conditions for the acquisition.

CRISPR Therapeutics' Casgevy Shows Commercial Progress as Gene Therapy Pipeline Advances

CRISPR Therapeutics and Vertex report encouraging progress with Casgevy, their approved gene therapy for sickle cell disease and beta-thalassemia, with 65 treatment centers now activated globally.

Pfizer Withdraws Sickle Cell Drug Oxbryta Globally Following Safety Concerns

Pfizer has voluntarily withdrawn its sickle cell disease therapy Oxbryta (voxelotor) from all global markets after discovering an imbalance in deaths during clinical trials.

New York Man Becomes First in State to Be Cured of Sickle Cell Disease with Lyfgenia Gene Therapy

21-year-old Sebastien Beauzile has been successfully treated for sickle cell disease at Cohen Children's Medical Center using Bluebird Bio's Lyfgenia gene therapy, becoming the first New Yorker to receive this breakthrough treatment.

Bristol Myers Squibb Acquires 2seventy bio for $286 Million to Gain Full Control of CAR-T Therapy Abecma

Bristol Myers Squibb has agreed to acquire 2seventy bio for $286 million, ending the profit-sharing arrangement for the BCMA-targeted CAR-T therapy Abecma used in multiple myeloma treatment.

Bristol Myers Squibb Acquires 2seventy Bio for $102 Million as Gene Therapy Sector Faces Valuation Challenges

Bristol Myers Squibb has acquired 2seventy Bio for $102 million net, just weeks after Bluebird Bio, 2seventy's parent company, was sold for a mere $30 million, highlighting significant valuation challenges in the gene therapy sector.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.